FDA approves Johnson & Johnson's ketamine-derived nasal spray for depression as standalone treatment
2025-01-23Fortune on MSN.com
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population. ...Read more
Recommendations
2025-01-23The Jamaica Observer
Loading...